Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK

Author： Guest Julian F.   Clegg John P.   Davie Alison M.   McCloskey Eugene  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.21, Iss.5, 2005-05, pp. : 805-818

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients

By  

Oncology, Vol. 69, Iss. 1, 2005-09 ,pp. : 35-43

Karger

Access to resources Recommend Favorite

Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis

By Hatoum Hind T.   Lin Swu-Jane   Guo Amy   Lipton Allan   Smith Matthew R.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 55-62

Informa Healthcare

Access to resources Recommend Favorite

High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

By  

Urologia Internationalis, Vol. 90, Iss. 1, 2012-11 ,pp. : 56-61

Karger

Access to resources Recommend Favorite

Zoledronic acid in the management of osteoporosis: the HORIZON trials

By Lewiecki E Michael  

Therapy, Vol. 5, Iss. 6, 2008-11 ,pp. : 829-835

Future Medicine

Access to resources Recommend Favorite

Family history and outcome of young patients with breast cancer in the UK (POSH study)

By  

BRITISH JOURNAL OF SURGERY, Vol. 102, Iss. 8, 2015-07 ,pp. : 924-935

John Wiley & Sons Inc

Access to resources Recommend Favorite